Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT00316940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT00316940
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Oncotherapeutics
- Industry
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- bortezomib Drug
- samarium Sm 153 lexidronam pentasodium Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- May 31, 2008
- Completion
- Jan 31, 2011
- Last update posted
- Sep 19, 2013
2005 – 2011
United States locations
- U.S. sites
- 4
- U.S. states
- 2
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309-0633 | — |
| Hematology-Oncology Medical Group of Fresno, Incorporated | Fresno | California | 93720 | — |
| Not listed | West Hollywood | California | 90069 | — |
| Center for Cancer and Blood Disorders at Suburban Hospital | Bethesda | Maryland | 20817 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00316940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2013 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00316940 live on ClinicalTrials.gov.